PMN310 is a humanized monoclonal antibody (mAb) designed and developed to selectively target only soluble amyloid-beta ...
Webcasts of the presentations will be available and may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com. A replay of the webcasts will be archived on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback